|
|
Hokkaido University Collection of Scholarly and Academic Papers >
Hokkaido University Hospital >
Peer-reviewed Journal Articles, etc >
Multicenter, prospective, observational study of chemotherapy-induced dysgeusia in gastrointestinal cancer
| Title: | Multicenter, prospective, observational study of chemotherapy-induced dysgeusia in gastrointestinal cancer |
| Authors: | Ken, Ito Browse this author | | Satoshi, Yuki Browse this author | | Hiroshi, Nakatsumi Browse this author | | Kawamoto, Yasuyuki Browse this author →KAKEN DB | | Harada, Kazuaki Browse this author | | Nakano, Shintaro Browse this author | | Saito, Rika Browse this author | | Ando, Takayuki Browse this author | | Sawada, Kentaro Browse this author | | Yagisawa, Masataka Browse this author | | Ishiguro, Atsushi Browse this author | | Dazai, Masayoshi Browse this author | | Iwanaga, Ichiro Browse this author | | Hatanaka, Kazuteru Browse this author | | Sato, Atsushi Browse this author | | Matsumoto, Ryusuke Browse this author | | Shindo, Yoshiaki Browse this author | | Tateyama, Miki Browse this author | | Muranaka, Tetsuhito Browse this author | | Katagiri, Masaki Browse this author | | Yokota, Isao Browse this author →KAKEN DB | | Sakata, Yuh Browse this author | | Sakamoto, Naoya Browse this author →KAKEN DB | | Komatsu, Yoshito Browse this author →KAKEN DB |
| Keywords: | Dysgeusia | | Taste disorder | | Chemotherapy | | Gastrointestinal cancer | | Polaprezinc | | Zinc acetate hydrate |
| Issue Date: | 1-Jun-2022 |
| Publisher: | Springer |
| Journal Title: | Supportive Care in Cancer |
| Volume: | 30 |
| Issue: | 6 |
| Start Page: | 5351 |
| End Page: | 5359 |
| Publisher DOI: | 10.1007/s00520-022-06936-4 |
| Abstract: | Purpose Dysgeusia is an adverse event caused by chemotherapy. Although retrospective studies have shown zinc administration improves dysgeusia, there have been no prospective studies. The present study examined effects of zinc therapy on dysgeusia in patients with gastrointestinal cancer. Methods This multicenter, prospective, observational study enrolled patients with dysgeusia during chemotherapy treatment. Patients received no intervention (control), polaprezinc p.o., or zinc acetate hydrate p.o., and serum zinc levels were measured at 0 (baseline), 6, and 12 weeks. Dysgeusia was assessed using CTCAE v5.0 and subjective total taste acuity (STTA) criteria using questionnaires at baseline and 12 weeks. Results From February 2020 to June 2021, 180 patients were enrolled from 17 institutes. There were no differences in mean baseline serum zinc levels among the groups (67.3, 66.6, and 67.5 mu g/dL in the no intervention, polaprezinc, and zinc acetate hydrate groups, respectively. P = 0.846). The changes in mean serum zinc levels after 12 weeks were - 3.8, + 14.3, and + 46.6 mu g/dL, and the efficacy rates of dysgeusia were 33.3%, 36.8%, and 34.6% using CTCAE and 33.3%, 52.6%, 32.7% using STTA in the no intervention, polaprezinc, and zinc acetate hydrate groups, respectively. The STTA scores improved in all groups, with significant improvement observed in the polaprezinc group compared with the no intervention group (P = 0.045). Conclusion There was no significant correlation between the degree of serum zinc elevation and improvement in dysgeusia, suggesting that polaprezinc, but not zinc acetate hydrate, was effective in improving chemotherapy-induced dysgeusia. |
| Type: | article |
| URI: | http://hdl.handle.net/2115/85674 |
| Appears in Collections: | 北海道大学病院 (Hokkaido University Hospital) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)
|
|
